What Really Matters for Cancer Care - Health Systems Strengthening or Technological Innovation?
Aggarwal, A;
Lievens, Y;
Sullivan, R;
Nolte, E;
(2022)
What Really Matters for Cancer Care - Health Systems Strengthening or Technological Innovation?
Clinical oncology, 34 (7).
pp. 430-435.
ISSN 0936-6555
DOI: https://doi.org/10.1016/j.clon.2022.02.012
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Modern medicine has long been characterised by a relentless focus on innovation and the expansion of biomedical and scientific boundaries, with cancer at the vanguard. The more recent advent of precision medicine has pushed boundaries even further, with genomic advances allowing us to decipher the innate biology of a cancer and expand the repertoire of targets amenable to systemic therapies. However, this ‘pharmaceuticalisation of cancer care’ risks being highly reductionist in our pursuit of improving outcomes, pivoting research and public sentiment away from the evidence-based reality that early diagnosis as well as high-quality surgery and radiotherapy underpin better cancer outcomes for populations. The new generation of precision cancer medicines, especially immuno-oncology, are expected to contribute to 70% of the total cost of active care by 2025, whereas at the same time nearly 50% of the global population has little or no access to diagnostics or palliative care, and up to 80% have no access to timely, safe and affordable surgery and radiotherapy, let alone basic generic chemotherapy.
Description: This is an author accepted manuscript version of an article accepted for publication, and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0